secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001493152-23-024286
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera appoints Dr. Heikki Lanckriet to Board under settlement with major stockholder
--------------------------------------------------------------------------------

- Dr. Heikki Lanckriet appointed to Board of Directors effective July 7, 2023 as Class I director through 2025 annual meeting.
- Nominated by Biofrontera AG under April 2023 settlement agreement between the companies.
- Compensation: $40,250 annual retainer (pro-rated for 2023) plus annual stock award.
- Lanckriet serves as CEO/CSO of 4basebio PLC and on Biofrontera AG's Supervisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223024286/0001493152-23-024286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223024286/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer